MIST News and Press, Milestone Pharmaceuticals Inc. From 03/24/20

Milestone Pharmaceuticals (NASDAQ: MIST )  -74%  on failed etripamil study. More news on: Milestone Pharmaceuticals Inc., Invesco Mortgage Capital Inc., Baudax Bio, Inc., Stocks on the move, , Read more ...

Compugen (NASDAQ: CGEN ) initiated with Buy rating and $16 (156% upside) price target at SunTrust. Shares up  9%  premarket. More news on: Compugen Ltd., Incyte Corporation, NextCure, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Gainers: HBT   +29.2% .   CCOI   +14.5% . CMLS   +13.9% . SPKE   +13.3% . IMMU   +11.5% . More news on: HBT Financial, Inc., Cogent Communications Holdings, Inc., Cumulus Media Inc., Stocks on the move, , News on ETFs Read more ...

A Phase 3 clinical trial, NODE-301 , evaluating Milestone Scientific's (NASDAQ: MIST ) etripamil nasal spray in patients with paroxysmal supraventricular tachycardia (PSVT) (abnormally fast heartbeat that starts above the lower chambers of the heart) did not achieve the primary endpoint. ...

–  Study missed primary endpoint of mean time to conversion of SVT to SR over a five-hour period following dosing (p=0.12) – –  Etripamil showed rapid conversion of SVT to SR during the first 45 minutes (p=0.02), consistent with its known pharmacology ȁ...

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...

Milestone Pharmaceuticals (NASDAQ: MIST) expects to report top-line data from its phase 3 Node-301 clinical trial before the end of the month. If positive, the company expects to use the trial results to file for approval with the U.S. Food and Drug Administration (FDA). The company believes...

Tocagen Continues Merger-Fueled Upswing Tocagen ( TOCA ) stock shot up as the company follows through its previous announcement about a merger with Forte Biosciences, an obscure pharmaceuticals firm with FB-401 as its lead candidate. FB-401 is a topical drug designed to treat inflammatory ...

Milestone Pharmaceuticals (NASDAQ: MIST ): Q4 GAAP EPS of -$0.75 misses by $0.23 . Cash, Cash Equivalents and Short-term Investments of $119.8M Press Release More news on: Milestone Pharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news,

– Topline data from Phase 3 NODE-301 trial of etripamil in patients with PSVT expected this month –   MONTREAL and CHARLOTTE, N.C. , March 6, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the devel...